Which has higher valuation & earnings, MBX or KYTX?

MBX Biosciences is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.21 N/A Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A

Is MBX or KYTX more profitable?

MBX Biosciences' return on equity of -24.52% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -24.52% -23.59% Kyverna Therapeutics N/A -81.88% -64.87%

Does the media favor MBX or KYTX?

In the previous week, MBX Biosciences and MBX Biosciences both had 1 articles in the media. MBX Biosciences' average media sentiment score of 0.88 beat Kyverna Therapeutics' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyverna Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to KYTX or AGIO?

In the previous week, Kyverna Therapeutics and Kyverna Therapeutics both had 1 articles in the media. Agios Pharmaceuticals' average media sentiment score of 1.34 beat Kyverna Therapeutics' score of 0.00 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Agios Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KYTX or ANIP?

In the previous week, Kyverna Therapeutics and Kyverna Therapeutics both had 1 articles in the media. ANI Pharmaceuticals' average media sentiment score of 1.75 beat Kyverna Therapeutics' score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ANI Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is KYTX or LKFT more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.88% -64.87% Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A

Kyverna Therapeutics (KYTX) Competitors

$8.63 +0.20 (+2.42%)

Closing price 06/24/2026 03:59 PM Eastern

Extended Trading

$8.62 -0.02 (-0.17%)

As of 06/24/2026 08:00 PM Eastern

Compare

KYTX vs. MBX, AGIO, ANIP, LKFT, and BHC

Should you buy Kyverna Therapeutics stock or one of its competitors? MarketBeat compares Kyverna Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kyverna Therapeutics include MBX Biosciences (MBX), Agios Pharmaceuticals (AGIO), ANI Pharmaceuticals (ANIP), Lakefront Biotherapeutics American Depositary Shares (LKFT), and Bausch Health Cos (BHC). These companies are all part of the "pharmaceutical products" industry.

How does Kyverna Therapeutics compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Kyverna Therapeutics (NASDAQ:KYTX) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

MBX Biosciences has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market.

In the previous week, MBX Biosciences and MBX Biosciences both had 1 articles in the media. MBX Biosciences' average media sentiment score of 0.88 beat Kyverna Therapeutics' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kyverna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MBX Biosciences is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A

MBX Biosciences' return on equity of -24.52% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Kyverna Therapeutics	N/A	-81.88%	-64.87%

18.1% of Kyverna Therapeutics shares are owned by institutional investors. 52.2% of MBX Biosciences shares are owned by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MBX Biosciences presently has a consensus price target of $60.22, indicating a potential upside of 24.43%. Kyverna Therapeutics has a consensus price target of $30.00, indicating a potential upside of 247.46%. Given Kyverna Therapeutics' higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

MBX Biosciences beats Kyverna Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Agios Pharmaceuticals?

Kyverna Therapeutics (NASDAQ:KYTX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

18.1% of Kyverna Therapeutics shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Kyverna Therapeutics and Kyverna Therapeutics both had 1 articles in the media. Agios Pharmaceuticals' average media sentiment score of 1.34 beat Kyverna Therapeutics' score of 0.00 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agios Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyverna Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 247.46%. Agios Pharmaceuticals has a consensus price target of $40.89, suggesting a potential upside of 12.70%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Kyverna Therapeutics is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Kyverna Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Agios Pharmaceuticals	$54.03M	39.93	-$412.78M	-$7.25	N/A

Kyverna Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Kyverna Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. Agios Pharmaceuticals' return on equity of -34.11% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%

Summary

Kyverna Therapeutics beats Agios Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Kyverna Therapeutics compare to ANI Pharmaceuticals?

Kyverna Therapeutics (NASDAQ:KYTX) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

ANI Pharmaceuticals has a net margin of 9.98% compared to Kyverna Therapeutics' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ANI Pharmaceuticals has higher revenue and earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
ANI Pharmaceuticals	$883.37M	2.13	$78.34M	$3.95	20.94

Kyverna Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

Kyverna Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 247.46%. ANI Pharmaceuticals has a consensus target price of $107.33, suggesting a potential upside of 29.75%. Given Kyverna Therapeutics' higher possible upside, equities research analysts plainly believe Kyverna Therapeutics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Kyverna Therapeutics and Kyverna Therapeutics both had 1 articles in the media. ANI Pharmaceuticals' average media sentiment score of 1.75 beat Kyverna Therapeutics' score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

ANI Pharmaceuticals beats Kyverna Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Kyverna Therapeutics (NASDAQ:KYTX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kyverna Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 247.46%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $36.50, suggesting a potential upside of 25.82%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Kyverna Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.13

Kyverna Therapeutics has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Kyverna Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.52	$363.05M	-$1.41	N/A

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 3 mentions for Lakefront Biotherapeutics American Depositary Shares and 1 mentions for Kyverna Therapeutics. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.61 beat Kyverna Therapeutics' score of 0.00 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lakefront Biotherapeutics American Depositary Shares beats Kyverna Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Bausch Health Cos has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market.

Kyverna Therapeutics has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Kyverna Therapeutics' return on equity of -81.88% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-11.47%	-2,922.77%	5.63%
Kyverna Therapeutics	N/A	-81.88%	-64.87%

In the previous week, Kyverna Therapeutics had 1 more articles in the media than Bausch Health Cos. MarketBeat recorded 1 mentions for Kyverna Therapeutics and 0 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.00 equaled Kyverna Therapeutics'average media sentiment score.

Company	Overall Sentiment
Bausch Health Cos	Neutral
Kyverna Therapeutics	Neutral

Bausch Health Cos currently has a consensus price target of $8.00, indicating a potential upside of 60.48%. Kyverna Therapeutics has a consensus price target of $30.00, indicating a potential upside of 247.46%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Bausch Health Cos has higher revenue and earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.18	$157M	-$3.24	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A

Summary

Bausch Health Cos and Kyverna Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Kyverna Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYTX vs. The Competition

Export

Metric	Kyverna Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$512.50M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-2.63	20.50	25.37	23.95
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	2.24	8.26	10.76	6.41
Net Income	-$161.31M	$23.91M	$3.56B	$337.14M
7 Day Performance	6.99%	2.12%	0.99%	-1.06%
1 Month Performance	-0.42%	2.40%	0.79%	0.49%
1 Year Performance	181.24%	57.09%	30.25%	28.43%

Kyverna Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYTX Kyverna Therapeutics	2.1701 of 5 stars	$8.63 +2.4%	$30.00 +247.5%	+170.7%	$512.50M	N/A	N/A	96
MBX MBX Biosciences	1.7971 of 5 stars	$40.09 +2.8%	$60.22 +50.2%	N/A	$1.91B	N/A	N/A	N/A
AGIO Agios Pharmaceuticals	2.8028 of 5 stars	$31.84 +0.1%	$40.89 +28.4%	+8.6%	$1.89B	$54.03M	N/A	390	Positive News
ANIP ANI Pharmaceuticals	4.4503 of 5 stars	$83.00 +0.9%	$107.33 +29.3%	+23.5%	$1.89B	$883.37M	21.01	600	Positive News Analyst Upgrade
LKFT Lakefront Biotherapeutics American Depositary Shares	2.1058 of 5 stars	$28.18 -1.7%	$36.50 +29.5%	+4.9%	$1.86B	$1.26B	N/A	1,310

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYTX) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. MBX, AGIO, ANIP, LKFT, and BHC

How does Kyverna Therapeutics compare to MBX Biosciences?

Summary

How does Kyverna Therapeutics compare to Agios Pharmaceuticals?

Summary

How does Kyverna Therapeutics compare to ANI Pharmaceuticals?

Summary

How does Kyverna Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Kyverna Therapeutics compare to Bausch Health Cos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. MBX, AGIO, ANIP, LKFT, and BHC

How does Kyverna Therapeutics compare to MBX Biosciences?

Which has more risk and volatility, MBX or KYTX?

Does the media favor MBX or KYTX?

Which has higher valuation & earnings, MBX or KYTX?

Is MBX or KYTX more profitable?

Do insiders & institutionals believe in MBX or KYTX?

Do analysts recommend MBX or KYTX?

Summary

How does Kyverna Therapeutics compare to Agios Pharmaceuticals?

Do institutionals and insiders hold more shares of KYTX or AGIO?

Does the media refer more to KYTX or AGIO?

Do analysts prefer KYTX or AGIO?

Which has stronger earnings and valuation, KYTX or AGIO?

Which has more risk and volatility, KYTX or AGIO?

Is KYTX or AGIO more profitable?

Summary

How does Kyverna Therapeutics compare to ANI Pharmaceuticals?

Is KYTX or ANIP more profitable?

Do institutionals & insiders hold more shares of KYTX or ANIP?

Which has better valuation and earnings, KYTX or ANIP?

Which has more volatility and risk, KYTX or ANIP?

Do analysts prefer KYTX or ANIP?

Does the media refer more to KYTX or ANIP?

Summary

How does Kyverna Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Do insiders & institutionals hold more shares of KYTX or LKFT?

Do analysts recommend KYTX or LKFT?

Which has more risk and volatility, KYTX or LKFT?

Is KYTX or LKFT more profitable?

Which has better earnings and valuation, KYTX or LKFT?

Does the media refer more to KYTX or LKFT?

Summary

How does Kyverna Therapeutics compare to Bausch Health Cos?

Do insiders and institutionals have more ownership in BHC or KYTX?

Which has more risk & volatility, BHC or KYTX?

Is BHC or KYTX more profitable?

Does the media prefer BHC or KYTX?

Do analysts recommend BHC or KYTX?

Which has better earnings and valuation, BHC or KYTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools